Medistim

Regulatory Filings • Oct 13, 2014

Medistim launches its new product MiraQ Cardiac at EACTS

Medistim launches its new product MiraQ Cardiac at EACTS

(Oslo, 13 October 2014) Medistim ASA (OSE: MEDI), a

Norwegian company that develops and commercializes

medical equipment for use in cardiac, vascular and

transplant surgery, announces that they launch its

new product MiraQ Cardiac in the European market.

The launch takes place at the annual European

Association for Cardiac-Thoracic Surgery, EACTS,

which takes place in Milan, Italy from the 12th to

the 14th of October.

MiraQ is Medistim's fourth generation of systems for

intraoperative guidance and quality assessment of

cardiac, vascular and transplant surgery. The system

platform combines "state-of-the-art" blood flow

measurement (TTFM; transit time flow measurement) and

ultrasound imaging. Compared with previous

generations, the new platform is totally upgraded

with new operating system, user interface and

electronic and mechanical components designed for the

future. The platform is flexible, modular and allows

for customer adaptations, providing exciting

commercial opportunities. The platform provides a

good foundation for Medistim's development of new

products in the future.

There is growing interest and consensus among opinion

leaders that bypass grafts and anastomoses should be

verified with a combination of intraoperative

ultrasound imaging and blood flow measurement during

surgery, and that this should become the new standard

of care. For this to become a reality, it is crucial

that technology and methods are not regarded as

obstacles in the daily routine. Medistim's philosophy

is to put the user in focus, simplify and adapt the

product to fit different user groups.

The first product to be launched based on the new

platform is MiraQ Cardiac. With MiraQ Cardiac, we

have simplified the system, while adding new features

that enhance the value and user experience for this

client group. Among other things, there is developed

a new functionality, Guided Workflows, which assists

the user with a standardized approach to quality

assurance. This makes intraoperative quality both

easier to learn and adopt into daily clinical

practice. MiraQ Cardiac has been tested by selected

customers since June this year and the feedback is

positive.

Medistim has previously announced that they want to

focus more specifically towards vascular surgery, and

the new MiraQ platform provides a good basis for

developing a product targeted for vascular

applications.

"MiraQ is a unique platform that will make it even

easier to plan, guide, assess quality and perform

surgery" says Kari E. Krogstad, CEO of Medistim ASA,

and continues: "We are proud to present a new

generation of Medistim products based on modern

technology and software. We are convinced that the

MiraQ platform will provide an important foundation

for the company's future and growth. The launch of

MiraQ is an important milestone and an important

step toward realizing our vision to make graft

patency quality assurance standard clinical practice

during by-pass surgery. "

The MiraQ platform currently has CE approval and the

product can be sold in Europe and all other countries

that accept this approval. Medistim will seek

clearance from the US Food and Drug Administration

(FDA) for the sale of MiraQ in the United States. In

parallel Medistim will seek approval from the

Ministry of Health, Labor and Welfare (MHLW) for

clearance in the Japanese market. It is expected that

these approvals will be in place by the end of 2015.

For more information, contact:

President & CEO, Kari E. Krogstad, Medistim ASA

Tel: + 47 918 38 110

Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA

Tel: + 47 906 59 940

Email: thomas.jakobsen@medistim.com

About Medistim

Medistim was established in 1984, and has a track

record of profitable growth over the past >10 years.

The company is a pioneer within its segment, and

continues to invest in new product development.

Medistim has wholly owned subsidiaries with sales

organizations in the US, Germany, Denmark, UK and

Norway, in addition to the around 50 distributors in

Europe, Asia, Middle East, Africa and South

America. For more information, visit the Medistim

home page: www.Medistim.com